Sponsored by

VGoodiez 420EDC
  • Welcome to VaporAsylum! Please take a moment to read our RULES and introduce yourself here.
  • Need help navigating the forum? Find out how to use our features here.
  • Did you know we have lots of smilies for you to use?

Law The Cannabis Chronicles - Misc Cannabis News

"The officials pointed out that Fogel’s charges are “similar to those of Brittney Griner,”

Poor smuck isn't part of the right demographic....on at least a couple of criteria.

My personal view is that nobody....as in NOBODY...goes to Russia with cannabis and doesn't know that they are consciously breaking Russian law.


GOP Senator And Former Ambassador Want Biden’s Help Freeing A Medical Marijuana Patient Jailed In Russia


A U.S. senator and a former ambassador are imploring the Biden administration to “immediately” escalate diplomatic efforts to secure the return of an American imprisoned in Russia over possession of medical cannabis that he lawfully obtained in Pennsylvania.

Sen. Steve Daines (R-MT) and former U.S. Ambassador to Russia Michael McFaul sent a letter to Secretary of State Antony Blinken on Wednesday, requesting that the government formally designate Marc Fogel as wrongfully detained and “prioritize securing his release.”

“He is serving an unjust and unwarranted 14-year sentence of hard labor in a Russian prison for drug trafficking due to possession of medically prescribed medical marijuana,” the letter says. “This severe sentence is of particular concern as he is facing deteriorating health conditions that could potentially result in this judgment serving as a life sentence.”

The officials pointed out that Fogel’s charges are “similar to those of Brittney Griner,” an American basketball player who was imprisoned in Russia over possession of vape cartridges containing cannabis oil and designated by the State Department as wrongfully detained before being released as part of a prisoner swap that the Biden administration negotiated.

The letter says “similar actions by the State Department are warranted and every effort to secure [Fogel’s] release should be made, including designating him as wrongfully detained.”

Late last year, more than two dozen members of Congress called on the State Department to escalate diplomatic efforts to secure the release of Fogel, calling his incarceration over marijuana that he used to treat chronic pain “unconscionable.”

The White House said last year it was actively investigating Fogel’s case, and lawmakers have been keeping the pressure on to ensure it’s doing all that it can to secure his release.

When asked about the administration’s work to secure the release of other Americans like Fogel who are imprisoned abroad, Press Secretary Karine Jean-Pierre deferred to the State Department, arguing that “every case is different” and saying she didn’t want to get ahead of any ongoing diplomatic efforts.

Sen. Bob Casey (D-PA) also led a letter with other senators last year that similarly asked the State Department to classify the citizen, an American teacher, as “wrongfully detained.” That came shortly after other bipartisan members of Pennsylvania’s congressional delegation similarly pled with the State Department to escalate Fogel’s case, drawing parallels between his and Griner’s cannabis-related convictions.

As State Department spokesperson Ned Price explained last year, officials take into account 11-point criteria when determining whether a given case amounts to a wrongful detention. For example, if the U.S. has reason to believe that due process is being impaired, that the person was arrested solely because they are a U.S. national or that they are innocent of the stated charges, that would warrant a wrongful detention designation.

Russia, for its part, has taken a particularly strong stance against reforming cannabis policy at the international level through the United Nations. And it condemned Canada for legalizing marijuana nationwide.

The deputy of Russia’s Ministry of Foreign Affairs said last year that legalization efforts in the U.S. and Canada are matters “of serious concern for us,” according to a social media post from the office’s official account. “It is worrisome that several Member States of the [European Union] are considering violating their drug control obligations.”
 

Where Presidential Candidate Mike Pence Stands On Marijuana


Former Vice President Mike Pence has officially entered the race for the Republican 2024 presidential nomination, putting his drug policy positions and actions into focus again.

Pence, who also served as governor of Indiana, has long opposed even incremental cannabis reform efforts at the state and federal levels. During his time in the White House, for example, he spoke out against an attempt to pass a marijuana banking measure as part of a pandemic relief package.

Over his 16 years in Congress, he also consistently voted against legislation to protect state medical cannabis programs from federal interference.
He’s asserted that he believes cannabis is a gateway to other illicit drugs, and has voiced disapproval of decriminalizing simple possession. And while as governor he pushed the Indiana legislature to ramp up criminalization of illicit substances—saying Indiana was “leaning into the war on drugs”—he also signed into law a large-scale criminal justice bill that included provisions to reduce penalties for simple marijuana possession.

Pence also opposed syringe exchange programs, a harm reduction resource meant to curb the spread of diseases like HIV from contaminated needles, but he eventually authorized the service under mounting pressure from public health officials.

He’s competing for the nomination against several GOP candidates, including his former 2016 running mate President Donald Trump, former New Jersey Gov. Chris Christie (R), Florida Gov. Ron DeSantis (R), U.S. Sen. Tim Scott (R-SC), former Arkansas Gov. Asa Hutchinson (R) and former South Carolina Gov. Nikki Haley (R).
Here’s where Republican presidential candidate Mike Pence stands on marijuana:

Legislation And Policy Actions​

Vice President (January 2017-January 2021)
In 2020, the vice president criticized lawmakers who sought to pass a bipartisan bill to protect banks that work with state-licensed marijuana businesses from federal penalties as part of a coronavirus relief package. He complained that the House-passed legislation “actually mentions marijuana more than it mentions jobs.”
“The American people don’t want some pork barrel bill coming out of the Congress when we’ve got real needs from working families,” he said.

That echoed points made by Pence’s chief of staff, who had described the Democratic proposal as a “liberal wish list” with “all sorts of things totally unrelated to coronavirus.”

“In one instance they have provided guarantees for banking access for marijuana growers,” the top Pence staffer said. “That has absolutely nothing to do with coronavirus.”

Pence served as vice president when the Justice Department under the administration rescinded the Obama-era Cole memo, which advised federal prosecutors to generally not pursue action against individuals for state-legal cannabis-related activity, except under a limited set of circumstances.
In 2020, the Justice Department asked a federal court to force California marijuana regulators to disclose documents about certain licensed cannabis businesses, and a federal court ruled that they must comply.

Under the Trump-Pence administration, the U.S. government backed a World Health Organization recommendation to remove marijuana from the most restrictive global drug scheduling category—though it opposed separate international cannabis reform proposals, including one to clarify that CBD is not under international control.

Another controversial administrative action concerned immigrants and marijuana. In April 2019, U.S. Citizenship and Immigration Services issued a memo stating that using marijuana or engaging in cannabis-related “activities” such as working for a dispensary—even in states where it’s legal—makes immigrants ineligible for citizenship because it means they don’t have “good moral character.”

In December 2019, the Justice Department issued a notice that it was seeking to make certain marijuana offenses, including misdemeanor possession, grounds to deny asylum to migrants.

One of the most significant cannabis developments to occur under the Trump-Pence administration was the federal legalization of hemp that was accomplished when the president signed the 2018 Farm Bill.

Indiana governor (January 2013-January 2017)
As governor, Pence signed lengthy criminal justice legislation in 2013 that included provisions to decrease penalties for simple marijuana possession in Indiana—reclassifying possession of more than 30 grams as a class A misdemeanor rather than a class D felony, for example—while also increasing penalties for those who deliver cannabis.

He advocated for increased criminalization as the legislation moved through the legislature, saying, “we need to focus on reducing crime, not reducing penalties”—and it was reported that Pence specifically sought more serious penalties for marijuana-related crimes as part of the bill.

“I think this legislation, as it moves forward, should still seek to continue to send a way strong message to the people of Indiana and particularly to those who would come into our state to deal drugs, that we are tough and we’re going to stay tough on narcotics in this state,” he said.

Pence’s deputy chief of staff participated in a summit in 2016 that focused on marijuana and synthetic drugs. The staffer said that the “safety and security of all Hoosiers is the highest priority for Governor Pence,” and he “recognizes the increasing negative role that drug abuse presents to our society.”

The governor faced significant criticism for resisting calls from experts and lawmakers to respond to a growing health crisis by permitting syringe exchange programs. Eventually, he did allow the services, however.

Pence also signed legislation in 2016 that reinstated a 10-year mandatory minimum sentence for people convicted of selling meth or heroin if they have a prior distribution charge on their record.

Another bill he approved established a commission to study drug misuse issues at the state and local levels.
And he also signed measures to promote access to the anti-overdose drug naloxone and provide immunity for people who call emergency personnel for people at risk of overdosing.


“We are today, through this effort, making life-saving medications available that have saved lives, and will continue to save lives from overdose in the state of Indiana,” Pence said at a signing ceremony in 2016.

Congress (January 2001-January 2017)
On six separate occasions, the then-congressman voted against appropriations amendments to prevent the Justice Department from using its federal funding to interference in the implementation of state medical cannabis programs. He did so in 2003, 2004, 2005, 2006, 2007 and 2012.
He also supported legislation that passed the House in 2008 that would have provided assistance to Mexico for counternarcotics enforcement purposes.

On The Campaign Trail​

It does not appear that Pence has spoken about cannabis policy since entering the race for the party’s nomination.

Previous Quotes And Social Media Posts​

During a gubernatorial debate in 2012, Pence said that he “would not support the decriminalization of marijuana” if elected.
“To be candid with you, growing up in the Hoosier State, I’ve seen too many people become involved with marijuana and have their lives sidetracked as a result,” he said.

“We’re to see marijuana become a gateway drug to even worse addictions on their part,” he said. “We need to get more serious about confronting the scourge of drugs, especially meth, in Indiana and decriminalization is not the right path in my honest opinion.”
In a 2020 debate, the then-vice president criticized current Vice President Kamala Harris over her prosecutorial record, without directly weighing in on marijuana reform, as she’d been asked about earlier in the debate.

“When you were when you were [district attorney] in San Francisco, when you left office, African Americans were 19 times more likely to be prosecuted for minor drug offenses than whites and Hispanics,” Pence said. “When you were attorney general of California, you increased report the disproportionate incarceration of blacks in California. You did nothing on criminal justice reform in California.”

Pence argued in favor of a proposed Mexican border wall during a speech at the Drug Enforcement Administration (DEA) headquarters in 2019, saying it would assist drug interdiction efforts.

“Our state has been leaning into the war on drugs and will continue to go hard after those who would profit from selling drugs to our kids,” he said during a State of the State address in 2016.

Personal Experience With Marijuana​

It does not appear that Pence has publicly commented on any personal experience with marijuana.

Marijuana Under A Pence Presidency​

The former vice president has previously identified as a proud drug warrior who does not believe in modest reform such as decriminalization, even if he did at one point sign broad legislation that including provisions to lower certain penalties for cannabis possession.

He also routinely voted against state-level marijuana program protections in Congress, subscribes to the gateway drug theory for cannabis and has been critical of Democratic efforts to enact marijuana banking reform.

All of that points to a potential presidency where marijuana policy reform would not be an administrative priority, though it’s unclear if he would proactively work to disrupt existing markets as public support for reform grows and a more state legalization laws are enacted.
 

Joe Biden’s long record supporting the war on drugs and mass incarceration, explained


Biden was a major Democratic leader in spearheading America’s war on drugs during the 1980s and ’90s.

Biden’s record puts him at sharp odds with where Democrats are today: He has one of the most punitive, “tough on crime” records on criminal justice issues within the 2020 field — more so than even opponents Kamala Harris or Amy Klobuchar, both of whom have also been criticized for their records. In fact, Biden was at the center of building federal policies that escalated the war on drugs and mass incarceration.

Consider one moment in Biden’s career: In 1989, at the height of punitive anti-drug and mass incarceration politics, Biden, then a senator, went on national television to criticize a plan from President George H.W. Bush to escalate the war on drugs. The plan, Biden said, didn’t go far enough.

“Quite frankly, the president’s plan is not tough enough, bold enough, or imaginative enough to meet the crisis at hand,” he said. He called not just for harsher punishments for drug dealers but to “hold every drug user accountable.” Bush’s plan, Biden added, “doesn’t include enough police officers to catch the violent thugs, not enough prosecutors to convict them, not enough judges to sentence them, and not enough prison cells to put them away for a long time” — a direct call for more incarceration.

As the head of the Senate Judiciary Committee in the late 1980s and early ’90s, Biden did not just support the war on drugs and mass incarceration; he wrote many of the laws that helped build a punitive criminal justice system. That included measures that enacted more incarceration, more prisons, and tougher prison sentences for drug offenses, particularly crack cocaine.

Much of this matched the rhetoric of the day, when Democrats and Republicans in the ’80s and ’90s pushed for lengthier prison sentences and “tough on crime” policies in general to combat a crime wave and a crack cocaine epidemic.

But as Democrats have since evolved on criminal justice issues to support reforms that reel back the war on drugs and incarceration, Biden’s record puts him at odds with where much of the party is today — with polls showing that most Democrats and most of the public back at least some reforms.

“There’s a tendency now to talk about Joe Biden as the sort of affable if inappropriate uncle, as loudmouth and silly,” Naomi Murakawa, author of The First Civil Right: How Liberals Built Prison America, told the Marshall Project in 2015. “But he’s actually done really deeply disturbing, dangerous reforms that have made the criminal justice system more lethal and just bigger.”

Biden has backtracked since the ’80s and ’90s. Before he left the Senate to become vice president, he pushed to pull back tougher prison sentences for crack cocaine — an effort that helped lead to a law that President Barack Obama signed in 2010. And he’s recently acknowledged his mistakes.

“I haven’t always been right,” Biden said earlier this year, speaking to criminal justice issues. “I know we haven’t always gotten things right, but I’ve always tried.” (Asked about Biden’s record, his spokesperson pointed to this speech, but did not respond to further questions.)

As a former vice president for a still-popular administration, Biden currently has very good standing among Democrats. National polls of the 2020 primary consistently put him at the top of the pack, leading all the other candidates who have announced so far. He also has fairly high favorability ratings; a recent survey from YouGov and the Economist found that “he is the sole Democratic contender whose overall favorability ratings are positive,” scoring very high numbers among Democrats in particular.

But Biden also faces a Democratic constituency that has, during his time in the public spotlight, changed dramatically on criminal justice issues. He spent years promoting “tough on crime” policies that led to mass incarceration — and now Democrats want the direct opposite, supporting an end to mass incarceration, the war on drugs, and aggressive policing. How Biden navigates the conflict between his past and his party’s present could help decide if he becomes the party’s nominee for president.

Biden didn’t just support the war on drugs. He authored large chunks of it.​


During the 1980s and ’90s, America was in the middle of a crack epidemic and a huge crime wave. In response to this, Republicans and Democrats competed to look “tough on crime” — enacting incredibly punitive policies at all levels of government that focused, in large part, on imprisoning as many people as possible. On the Republican side, these efforts were led by Ronald Reagan and George H.W. Bush. But on the Democratic side, Biden, as head of the Senate Judiciary Committee, was a major leader in these efforts.

He clashed with Bush throughout the late 1980s and early ’90s about crime and drugs — Bush would put out a proposal and Biden would try to go further. During a debate over a bill in 1991 (that would eventually become the 1994 crime law), Biden argued his plan was “much tougher than the president’s” and “provides for more penalties for death for more offenses than the [president’s] bill.” In response to Republican criticisms that his bill protected criminals, Biden claimed that “we do everything but hang people for jaywalking.”

In between the political squabbles, though, Biden really did help enact some very punitive legislation. Here are some examples from his record, drawn partly from Jamelle Bouie’s previous rundown at Slate:

  • Comprehensive Control Act: This 1984 law, spearheaded by Biden and Sen. Strom Thurmond (R-SC), expanded federal drug trafficking penalties and civil asset forfeiture, which allows police to seize and absorb someone’s property — whether cash, cars, guns, or something else — without proving the person is guilty of a crime.
  • Anti-Drug Abuse Act of 1986: This law, sponsored and partly written by Biden, ratcheted up penalties for drug crimes. It also created a big sentencing disparity between crack and powder cocaine; even though the drugs are pharmacologically similar, the law made it so someone would need to possess 100 times the amount of powder cocaine to be eligible for the same mandatory minimum sentence for crack. Since crack is more commonly used by black Americans, this sentencing disparity helped fuel big racial disparities in incarceration.
  • Anti-Drug Abuse Act of 1988: This law, co-sponsored by Biden, strengthened prison sentences for drug possession, enhanced penalties for transporting drugs, and established the Office of National Drug Control Policy, which coordinates and leads federal anti-drug efforts.
  • Violent Crime Control and Law Enforcement Act: This 1994 law, partly written by Biden, imposed tougher sentences and increased funding for prisons, contributing to the growth of the US prison population from the 1990s through the 2000s — a trend that’s only begun to reverse in the past few years. It also included other measures, such as the Violence Against Women Act that helped crack down on domestic violence and rape, a 10-year ban on assault weapons, funding for firearm background checks, and grant programs for local and state police.

In short, Biden helped write and pass two of the most important pieces of federal legislation in the federal war on drugs — the 1986 and 1988 laws — and, in particular, helped create the sentencing disparity for crack and powder cocaine. And he was at least partly behind other laws that perpetuated mass incarceration and increased police powers. (A caveat: The great majority of incarceration happens at local and state levels, where federal law doesn’t apply.)

As Washington Post opinion writer Radley Balko tweeted in 2015, “The martial/incarceral state has had no greater friend in Washington over the last 35 years than Joe Biden.”

This reflected the politics of the time, as Democrats competed with Republicans to look as tough as possible on crime. It was a Democratic president, Bill Clinton, who signed the 1994 crime law that Biden helped write. That was largely a response to public demand: Based on Gallup’s surveys, people were much more likely, particularly in the 1990s, to say that crime was the most important issue facing the country.

Since the mid-2000s, this has started to shift in the Democratic Party. With books like The New Jim Crow by Michelle Alexander and movements like Black Lives Matter, the party has especially paid attention to the vast racial disparities in the criminal justice system that make it more likely a black man will be locked up for longer for the same crimes as a white man.

It’s in this new context that Biden’s record starts to look very dated. While other politicians can claim that they were simply following the politics of the time, or say they never supported mass incarceration to begin with, Biden was a leader in this space — and he earnestly and enthusiastically pursued mass incarceration and the war on drugs.


Biden has tried to repent for some of his past​


Even before talk of his presidential run, and even before he became vice president, Biden did begin to distance himself from his past “tough on crime” record.

In 2008, he backed the Second Chance Act, which provides monitoring and counseling services to former prison inmates. In his last few years in the Senate, he supported the full elimination of the sentencing disparity between crack and powder cocaine. (The disparity was reduced from 100-to-1 to 18-to-1 in 2010 with the passage of the Fair Sentencing Act of 2010.)

Biden even offered somewhat of an apology during a 2008 Senate hearing:

Many have argued that this 100-to-1 disparity is arbitrary, unnecessary, and unjust, and I agree. And I might say at the outset in full disclosure, I am the guy that drafted this legislation years ago with a guy named Daniel Patrick Moynihan, who was the senator from New York at the time. And crack was new. It was a new “epidemic” that we were facing. And we had at that time extensive medical testimony talking about the particularly addictive nature of crack versus powder cocaine. And the school of thought was that we had to do everything we could to dissuade the use of crack cocaine. And so I am part of the problem that I have been trying to solve since then, because I think the disparity is way out of line.

He echoed the same apology recently, telling attendees at a breakfast commemorating Martin Luther King Jr. in January that “it was a big mistake when it was made. We thought, we were told by the experts, that crack, you never go back; it was somehow fundamentally different. It’s not different.”

And in July, Biden released a sweeping criminal justice reform plan that included, among other proposals, decriminalizing marijuana, eliminating mandatory minimum sentences for nonviolent crimes, ending the death penalty, abolishing private prisons, getting rid of cash bail, and discouraging the incarceration of children. The goal, Biden’s campaign said, was to cut incarceration and fix “the racial, gender, and income-based disparities in the system.”

Biden’s supporters also point out that he was never totally on board with some of the harsher measures in previous laws. For example, in a 1993 symposium sponsored by the US Sentencing Commission, Biden argued for undoing some mandatory minimums for drug offenses. “I think we’ve had all the mandatory minimums that we need. We don’t need the ones that we have,” he said. “But quite frankly, I don’t think I will prevail … I’ve watched how the process works. I am not at all hopeful there will be [enough] senators prepared to vote with me.”

This wasn’t just talk, Biden’s office previously told me. The 1994 law ultimately included what’s called a “safety valve” that allows a very limited number of low-level first-time drug offenders to avoid mandatory minimum sentences. This part of the 1994 law — along with the Violence Against Women Act, the 10-year ban on assault weapons, funding for firearm background checks, and grant programs for local and state police, which were all part of the 1994 measure — were some of the big-ticket items that led Biden to back the bill, even though he didn’t support every part of it, his office previously claimed.

But Biden has seemed proud of the 1994 law, even some of its “tough on crime” measures, until fairly recently. In his 2008 presidential campaign website, Biden’s campaign called the 1994 law the “Biden Crime Law.” And the website proudly touted a funding program in the law that encouraged states to effectively increase their prison sentences by paying them to build more prisons — a direct endorsement of more incarceration.

And in 2016, after CNBC asked Biden if he was ashamed of the 1994 law, Biden responded, “Not at all. As a matter of fact, I drafted the bill, if you remember.” He acknowledged that there were parts of the law he’d change, but argued that “by and large what it really did, it restored American cities.”

The effects of Biden’s actions are still felt today. When Trump called for greater use of the death penalty to fight the opioid epidemic, then–Attorney General Jeff Sessions cited the 1994 crime law that Biden worked to pass to put legal weight behind Trump’s plan.

There’s way less ambiguity in Biden’s record than in his opponents’ pasts​

Other presidential candidates have faced similar criticisms for their “tough on crime” records, including Sen. Kamala Harris (D-CA) for her work as a prosecutor and California’s attorney general and Sen. Amy Klobuchar (D-MN) for her time as a prosecutor in Minnesota.

But there are some nuances to these criticisms. Both Harris and Klobuchar did pursue some “tough on crime” policies, such as going after nonviolent offenders in certain cases. But Harris was also ahead of her time in, for example, supporting a “Back on Track” program that allowed first-time drug offenders to get a high school diploma and a job instead of prison time. And Klobuchar, while mostly an of-the-time “tough on crime” prosecutor in Hennepin County, worked with the Innocence Project to push for reforms in eyewitness identification and recorded police interviews — two big causes of the innocence movement at the time.

Biden’s record is much more straightforward. Sure, he occasionally spoke out against some tough measures, and some of his proposals included more funding for addiction treatment. But taken as a whole, Biden was very clearly and consistently pushing to make the criminal justice system much more punitive. His main criticisms of Bush and other Republicans were specifically that they weren’t “tough enough.”

As he said, touting the 1994 crime law:


The liberal wing of the Democratic Party is now for 60 new death penalties… The liberal wing of the Democratic Party has 70 enhanced penalties... The liberal wing of the Democratic Party is for 100,000 cops. The liberal wing of the Democratic Party is for 125,000 new state prison cells.

It remains unclear just how big an issue this will be for Biden. Various polls, including one from Vox and Morning Consult, have found the majority of Democrats support at least some criminal justice reform efforts. But other surveys, like Gallup’s, have also found that criminal justice issues aren’t a top-tier issue for voters — falling behind, in recent times, concerns about the government and poor leadership, immigration, the economy, and race relations.

Still, his record is bad news for criminal justice reformers. A constant worry in the criminal justice reform space is what would happen if, say, the crime rate started to rise once again. If that were to happen, there could be pressure on lawmakers — and it’d at least be easier for them — to go back to “tough on crime” views, framing more aggressive policing and higher incarceration rates in a favorable way.

Given that the central progressive claim is that these policies are racist and, based on the research, ineffective for fighting crime in the first place, any potential for backsliding in this area once it becomes politically convenient is very alarming.

The concern, then, is what would happen if crime started to rise under President Biden: Would he fall back on old “tough on crime” instincts, calling for harsh prison sentences once again?

“[E]ven if Biden has subsequently learned the error of his ways,” Branko Marcetic wrote for Jacobin, “the rank cynicism and callousness involved in his two-decade-long championing of carceral policies should be more than enough to give anyone pause about his qualities as a leader, let alone a progressive one.”

If enough Democrats come to that view, it could threaten Biden’s chances of becoming the next president of the United States.
 
I think all the candidates will take the easy way out and leave it up to the states. Leave federal law the way it is. Nobody has the balls to change the law federally. The Supreme Court certainly won’t. IMO they will need more progressive lawmakers from both parties - there’s a few but not enough. Then you have the older folks that are still calling it a gateway drug. WTF!:BangHead:

I’m happy with the cannabis situation in my state but I’m not a cannabis store owner.
 
I think all the candidates will take the easy way out and leave it up to the states. Leave federal law the way it is. Nobody has the balls to change the law federally.
I think we agree to the extent that we both view Fed level politicians as courageously leading from behind on this.

1686590030727.png
 

FILE - In this Aug. 18, 2020, file photo, mail delivery vehicles are parked outside a post office in Boys Town, Neb. (AP Photo/Nati Harnik, File)

FILE - In this Aug. 18, 2020, file photo, mail delivery vehicles are parked outside a post office in Boys Town, Neb. (AP Photo/Nati Harnik, File)


COLUMBIA, S.C. (WACH) — A US Postal Service worker is facing federal charges after officials said he knowingly delivered packages with marijuana to another man who is also facing charges.
According to recent indictments, Mjaan Roland and Lemont Darby are facing federal charges related to a drug conspiracy that took place on at least five separate occasions between March and April of 2022
 
To the DEA...AND, the feckless, do nothing, ass covering politicians who let them run rampant on the citizenship:

1686677671383.png





DEA Discusses Legal Status Of Minor Cannabinoids Like THCA And Hydrogenated CBD

The Drug Enforcement Administration (DEA) is weighing in on the legal status of lesser known cannabinoids such as THCA, delta-8 THC and hydrogenated CBD.

In a letter dated June 9, DEA said it was responding to a request for information about the scheduling status of the cannabis components under the Controlled Substances Act (CSA). There’s been some confusion about the legality of minor cannabinoids since hemp containing up to 0.3 percent delta-9 THC by dry weight was federally legalized under the 2018 Farm Bill.

The letter, posted on Reddit and analyzed by attorney Rod Kight, says that delta-8 THC and THC-hexyl are considered tetrahydrocannabinols. If products containing those naturally derived cannabinoids contain no more than 0.3 percent delta-9 THC, they are regarded as legal hemp. If the cannabinoid exceeds the THC limit, it is a Schedule I controlled substance.

Delta-8 THC has grown in popularity since hemp was legalized, entering marketplaces across the U.S., including in states where marijuana remains prohibited. But it’s often produced through a synthetic process that converts natural CBD into the intoxicating cannabinoid, and DEA has previously made clear that all synthetically produced cannabinoids are Schedule I substances.

The agency is also in the process of developing a final rule that’s expected to emphasize the synthetic cannabinoid ban under existing statute.

Kight’s post about the new letter focuses largely on delta-9 THCA, which is non-intoxicating but thought to possess anti-inflammatory properties. DEA said that, when assessing whether a plant is legal hemp or illegal marijuana, delta-9 THCA must be accounted for in a post-decarboxylation test for “total THC.”

“Accordingly, cannabis-derived delta-9-THCA does not meet the definition of hemp under the CSA because upon conversion for identification purposes as required by Congress, it is equivalent to delta-9-THC,” the letter, authored by Terrance Boos, chief of DEA’s Drug and Chemical Evaluation Section, says.

But Kight argues that the statute requiring post-decarboxylation testing only applies to production. So while it must be factored into the analysis of hemp that’s actively being produced, the same is not true of cannabis after it’s been harvested. In the right conditions, the concentration of delta-9 THCA can increase following harvesting.

Because the Farm Bill specifically says that post-production hemp products cannot contain more than 0.3 percent delta-9 THC (rather than total THC), that makes natural derivatives like delta-9 THCA federally legal, the attorney says.

“In summary, this DEA pronouncement is bound to create more confusion in an already confusing area of law; however, it should properly be read as simply restating the fact that hemp producers must comply with the total THC test in order to harvest their hemp,” Kight wrote. “Post-harvest (ie post-production), the 2018 Farm Bill’s definition of hemp clearly states that the delta-9 THC levels are what matters, not the levels of THCA.”

It’s not clear who inquired with DEA about the scheduling questions that prompted this response letter. Marijuana Moment reached out to the agency to confirm the veracity of the letter, which is similar other other responses it has provided, but a representative was not immediately available.

DEA also said that hexahydrocannabinol (HHC) “does not occur naturally in the cannabis plant and can only be obtained synthetically, and therefore does not fall under the definition of hemp.” It asserts the same about H4-CBD.

“If the product contains any quantity of synthetically produced tetrahydrocannabinol, it is controlled in schedule I of the CSA, unless it is specifically exempted or listed in another schedule (e.g., Marinol in schedule III under 21 CFR 1308.13(g)(1)),” the letter says. “If the product does not contain any quantity of synthetically produced tetrahydrocannabinol (or any other controlled substance), it is not controlled under the CSA.”

Earlier this year, DEA also separately clarified to Kight that two cannabinoids that have emerged in state markets—delta-8 THC-O and delta-9 THC-O—do not meet the federal definition of legal hemp and are therefore considered illegal controlled substances.
In another letter last year, DEA also effectively acknowledged that the cannabis seeds are generally uncontrolled and legal under existing statute, regardless of how much THC might end up being produced by plants cultivated from those seeds.

The agency announced in 2020 that it had removed the prescription CBD medication Epidiolex from Schedule V of the CSA, fully descheduling the cannabis medication.

Meanwhile, a recent DEA report shows that the agency seized more than 5.7 million marijuana plants last year, a demonstrable increase that bucks the trend that’s been observed over recent years amid the state legalization movement. Agents made far fewer cannabis-related arrests in 2022, however.

A former DEA officer is also taking the agency to federal court after being fired for testing positive for THC that he attributes to legal hemp-derived CBD oil he took for pain relief.
 

Cannabis companies laying off workers and exiting key markets


Pot stocks are cheap, but have they become too risky to buy?​


The cannabis industry is in free fall. Companies are struggling to find ways to grow, losses continue to pile up, and cash burn remains a big problem. For some businesses, that means it will take more than just layoffs to get things under control. Some large multi-state operators (MSOs) have been going to significant lengths this year and are planning to exit key markets.


Trulieve to exit Massachusetts​


Trulieve Cannabis (TCNNF) is one of the larger, more notable MSOs in the industry. For a while, the big knock on the business was it was too focused on the Florida market, where it has more than 100 dispensaries. It has expanded into other states since then, and one of the areas it was targeting as a key growth opportunity was the northeastern U.S.


But on June 1 the company said that it would be taking "additional measures to preserve cash and improve financial performance," which include ceasing operations in Massachusetts by the end of this year. The company also says that it will be exiting Nevada's wholesale market and getting rid of some retail outlets in California.


A month earlier, the company reported its latest earnings numbers and said that as of the end of May, its cash balance stood at $195 million. That's down from roughly $219 million at the end of 2022.


Curaleaf plans to exit multiple states​


Another big MSO, Curaleaf Holdings (CURLF -1.37%), previously said it would be winding down the majority of its operations in California, Colorado, and Oregon. In addition to Massachusetts, these are some of the nation's top marijuana markets, and all of them have legalized adult-use cannabis.


Unfortunately, with competition fierce in some of these markets and growth difficult to generate, companies are facing some difficult decisions when it comes to stopping the cash burn. Exacerbating the issue is that cannabis stocks have already generated abysmal returns over the past year, and issuing more shares to help fund operations could send share prices even lower; both Curaleaf and Trulieve trade near their 52-week lows, and are down more than 50% in the past 12 months.


Generating positive cash from day-to-day operations has been a challenge for both of these companies:


Are investors better off avoiding pot stocks?​


There's no light at the end of the tunnel right now for cannabis investors. The industry isn't proving to be resilient to inflation, and if a recession hits, things may get even worse for MSOs. Ironically, cannabis companies that aren't focused on expansion may be the best growth plays for investors in the long run. By conserving cash and improving their financials, those are the types of companies that may be in the best shape to come out from whatever economic challenges may lie ahead for the industry.


Cannabis companies were never safe buys to begin with given their lack of profitability and the U.S. federal ban on pot, and now they are even riskier. Although these stocks may seem cheap now, investors who are unprepared to take on the risk and are unwilling to potentially have to hold on to them for several years are better off going with safer growth stocks outside the cannabis industry.
 
Fed cannabis rescheduling update (Newsletter: June 16, 2023)

TOP THINGS TO KNOW

Health and Human Services Secretary Xavier Becerra told Marijuana Moment that his department and the Department of Justice are aiming to complete a review of cannabis’s federal scheduling status by the end of “this year.”


  • “Stay tuned. We hope to be able to get there pretty soon.”

The Senate Intelligence Committee approved legislation to protect applicants at CIA, NSA and other agencies from being denied security clearances solely because of past marijuana use.

The House of Representatives unanimously passed a resolution expressing “continued support” for U.S. citizen Marc Fogel, who is being detained in Russia under a “politicized, excessive sentence for his alleged offense” of possessing medical cannabis.

Wisconsin’s Republican Assembly speaker says lawmakers are crafting a medical cannabis legalization bill that could be filed this summer—but a top Democrat tells Marijuana Moment that her party hasn’t been invited to meetings about it.

The National Institute on Drug Abuse is looking to fund research on the impact of psychedelics legalization and decriminalization in cities and states across the country—including the effects of allowing regulated access to substances like psilocybin.

/ FEDERAL

The National Institute of Justice will host an event on the “merging of the e-cigarette and cannabis industries” on June 29.

The House bill to repeal the law blocking hemp industry participation by people with felony drug convictions got one new cosponsor for a total of eight.

The House bill to ease restrictions on hemp growers got one new cosponsor for a total of three.

/ STATES

Massachusetts Gov. Maura Healey (D) is recommending pardoning a handful of people, including a few with drug convictions.

Texas Gov. Greg Abbott (R) signed a bill allowing prosecutors to file murder charges against sellers of fentanyl if their customers die of overdoses.

Idaho Gov. Brad Little (R) claimed that “legalization of marijuana triggers numerous unintended consequences.”

An Ohio representative spoke about his marijuana legalization bill.

An Arkansas judge voided 27 medical cannabis laws, saying lawmakers overstepped their authority when changing the voter-approved constitutional amendment that legalized patient access.

A member of New York’s Cannabis Control Board stepped down amid criticism of the role that another agency he leads, the Dormitory Authority of the State of New York, has played in the slow rollout of legal dispensary locations. Separately, regulators approved additional retail licenses.

Arizona regulators announced a voluntary recall of marijuana products due to possible contamination with aspergillus and salmonella.

Michigan regulators revoked a marijuana business’s license over several alleged violations.

Colorado regulators are accepting public feedback on improvements to the cannabis social equity program.

Oregon regulators will consider proposed rules on the deadline for CBN manufacturers to meet general requirements on Friday.

Iowa’s Medical Cannabidiol Board will meet on Friday.

Tennessee’s Medical Cannabis Commission will meet on Friday.

The Massachusetts Cannabis Social Equity Advisory Board will meet on Friday.
 
“as quickly as we can” = glacial pace.


Feds Aim To Finish Cannabis Scheduling Review ‘This Year,’ Top Biden Official Tells Marijuana Moment

The head of the U.S. Department of Health and Human Services (HHS) is aiming to present President Joe Biden with a federal cannabis scheduling decision “this year” as agencies work “as quickly as we can” to complete an administrative review, Secretary Xavier Becerra told Marijuana Moment during a press briefing in Sacramento on Thursday.

While Becerra and other federal officials have previously emphasized that they are working “expeditiously” to carry out the cannabis review, which the president directed late last year, there’s been a lack of clarity about the specific timeline. Now the secretary has disclosed when he hopes to deliver on the president’s directive.

The Food and Drug Administration (FDA) under HHS is carrying out an eight-step scientific review into marijuana to determine whether it should be rescheduled, descheduled or remain in Schedule I, which is reserved for the most strictly controlled drugs under the Controlled Substances Act (CSA).

“What I can tell you is that the president instructed us at HHS—FDA in particular—to take a look at how we treat marijuana to see if we can update our review of marijuana as a drug and how we can make sure how we treat it going forward on the federal level,” Becerra told Marijuana Moment. “Places like California have already changed the laws, the federal government has not, and so we’ve been instructed and we’re underway with that review as we speak.”

He said that HHS, along with other agencies like the Drug Enforcement Administration (DEA), are “working together to try to see if we can give the president an answer that’s based on the science and the evidence. Stay tuned. We hope to be able to get there pretty soon—hopefully this year.”
 

NCAA panel recommends marijuana be dropped from banned substance list

Each NCAA division will have to pass legislation​


An NCAA panel on Friday called for the removal of marijuana from the organization’s list of banned drugs and suggested the testing should be limited to performance-enhancing substances.

The Committee on Competitive Safeguards and Medical Aspects of Sports recommended halting cannabis tests at such events until a final decision is made, likely this fall.

Marijuana plants grow at a secured growing facility in Washington County, New York, May 12, 2023. (AP Photo/Hans Pennink, File)
Legislation would still have to be introduced and approved by all three NCAA divisions to take effect. Administrators in Division II and III had asked the committee to study the issue.

The latest move from the panel comes as the U.S. is seeing more and more states allowing medical or recreational marijuana use. The committee increased the THC threshold needed for a positive test and recommended revamped penalties for athletes earlier this year. The threshold for THC was raised from 35 to 150 nanograms per millimeter, matching the World Anti-Doping Agency.

Last December, the committee noted that marijuana and its byproducts are not considered performance-enhancing substances.

The panel suggested stressing policies that focus on the potential threats from marijuana use and the need to reduce the harm and use of cannabis products instead of focusing on penalties.

For schools that test, the panel said officials should use those results to find "problematic" cannabis use.
 
Just another travesty brought to you by our feckless, cowardly, lead from behind, federal politicians.

Taylor...the woman mentioned in this article....plead guilty so this will not be a test case. But, there will be a case making it to SCOTUS that will pit the Constitution's individual enumerated rights against legislators and in particular the bureaucracy...in this case the DEA.


Your gun or your ganja: It’s illegal for marijuana users to own a gun


NEWPORT NEWS, Va. (WAVY) — You can own a gun, and you can use marijuana (at least in the states that have legalized it) — but you can’t do both at the same time, regardless of where you live.

“If you’re a normal, everyday Virginian who uses marijuana regularly, whether it’s lawfully or unlawfully, it doesn’t matter,” said attorney Billy Jackson. “You can’t possess a firearm because under federal law, as you point out, it’s still illegal to even possess marijuana.”

“Do you use marijuana?” is one of many “yes or no” questions on Form 4473 from the Bureau of Alcohol, Tobacco, Firearms and Explosives. Filling out the form is a requirement for gun purchasers in every state across the nation. Lying on that form is a federal crime.

“The federal government still looks at marijuana usage the same as they look at heroin or cocaine,” said Portsmouth Sheriff Michael Moore. Moore was a special agent in the ATF who worked on drug and gun trafficking cases.

It’s a law federal prosecutors believe Deja Taylor broke when she bought a 9-millimeter handgun from Winfree Firearms in July 2022. Her 6-year-old son would use that gun to shoot his teacher, Abby Zwerner, at a Virginia elementary school six months later.

Taylor recently pleaded guilty to a pair of federal charges — making a false statement when buying a gun and possessing a firearm while illegally using marijuana — in the case.

“That’s why we have these laws on the books,” Jackson said. “To hold these individuals accountable for both their own firearm possession and what flows, what kind of danger flows from that firearm possession. And here, that harm that flowed from it was just devastating.”

Jackson was a federal prosecutor for more than six years. He brought those same charges against many defendants, most often violent offenders he wanted to take off the streets quickly.

“It’s an easy charge to convict someone of,” Jackson said.

Late last month, after Minnesota legalized recreational marijuana, ATF issued a reminder that not only are marijuana users prohibited from owning a gun, but receiving, transporting, or shipping firearms and ammunition.

Smoking a joint one time isn’t enough to make buying a gun illegal. To prove those charges, Jackson said prosecutors must show that a person uses marijuana regularly.

“You have to have regular use. Daily use is preferred,” he said. “You have to show contemporaneous use. That they used it within a day or two or a week of being caught with the firearm. For example, the gold standard is when you find them with the firearm in one pocket and drugs in another.”

Medical marijuana users can’t own guns, either, according to federal law.

“It’s spelled out pretty well, and it has a warning: The use or possession of marijuana remains unlawful under federal law regardless of if it’s been legalized or decriminalized for medicinal or recreation purposes in the state where you reside,” Moore said of the ATF’s Form 4473.

The same federal view of marijuana can also cause headaches for air travelers.

“Hopefully in the very near future this form, and the federal government, will be able to address that change,” he continued.
 
First off, the title of this article is utterly misleading. In no way, shape, or form has the Biden admin committed to such an action much less a schedule.

"prepared to discuss descheduling cannabis" For fuck's sake...its been discussed ad nauseam for years and years. Is more endless government "discussions" going to unveil some new and previously unknown facts? Fuck no....BS article about a BS, temporizing statement.

And I love this....who gives a fuck what HHS and FDA says....DEA controls the schedule...IAW the Controlled Substance Act which put MJ on the schedule... and they are in DOJ.

But, perhaps you are not as cynical as I so here is the article.

Biden Admin confirms Marijuana descheduling happening THIS year

Is the United States about to see its biggest change to marijuana policy in recent decades?

Marijuana reform at the federal level is coming in the near future, says senior Biden officials.

During a press briefing in Sacramento, Calif., a few days ago, U.S. Secretary of Health and Human Services Xavier Becerra told Marijuana Moment senior editor Kyle Jaeger that the Biden administration is prepared to discuss descheduling cannabis in a significant reform in the post-drug war era. Vaping Post has extensively reported on national efforts to make legal recreational and medicinal cannabis, including decriminalizing possession. Becerra’s sentiments were additionally echoed in a Juneteenth declaration issued by President Joe Biden at the White House on June 16. This sentiment suggests a significant positioning for the administration to take on one of the biggest drug control policy changes in decades.

We’re underway with that review as we speak.

“[M]aking Juneteenth a Federal holiday was only one part of my administration’s efforts to advance racial equity and ensure that America lives up to its highest ideals,” Biden said in remarks published by the White House press office, adding that his administration has “taken action on marijuana reform by pardoning prior District of Columbia and Federal simple marijuana possession offenses and directed a review of marijuana scheduling.”

“We’re underway…”

On Jaeger’s end, he asked Becerra questions on marijuana scheduling at a press event that was focused on food science innovation. The former attorney general of California, Becerra channeled his home turf when he told Jaeger that big changes are coming. “What I can tell you is that the president instructed us at [Health and Human Services]—[Food and Drug Administration]in particular—to take a look at how we treat marijuana to see if we can update our review of marijuana as a drug and how we can make sure how we treat it going forward on the federal level,” Becerra said, via Marijuana Moment. He said that “we’re underway with that review as we speak.” At the time of this column, 23 states and the nation’s capital, Washington, D.C., are the only jurisdictions to permit recreational marijuana sales and consumption for adults aged 21 years and older. 38 states have legal medical marijuana programs in place. The self-governing U.S. territories of Guam and the Northern Mariana Islands also have legal recreational marijuana markets. Nearly half of the United States has recreational marijuana legalization in some form, with well over half with burgeoning medical marijuana markets. The review that Biden and Becerra refer to is considering whether marijuana should remain on the Drug Enforcement Administration’s (DEA) scheduling of the substances as a Schedule I narcotic is justified under federal law.

About seven in 10 Louisiana residents support legal recreational marijuana use.

The DEA defines a Schedule I as applying to “drugs, substances, or chemicals” with “no currently accepted medical use and high potential for abuse.” Examples of Schedule I substances include hard drugs like heroin, meth, psychedelics including LSD and ecstasy, peyote (outside of religious exceptions), and marijuana. This justification was outlined by the Controlled Substances Act of 1970, which was advocated for and signed by then-President Richard Nixon, a Republican. Reviewing the scheduling of marijuana under the Controlled Substances Act includes a regulatory, public health, economic, and population analysis. If the descheduling or rescheduling of marijuana occurs this year, it wouldn’t invalidate laws in states where possession and the distribution of the drug are unlawful.

It’s about time

Advocates for marijuana liberalization have lobbied for marijuana scheduling reform in light of dozens of states taking steps to legalize or decriminalize marijuana in some form or another. This action, however, takes on political dimensions that are going to be very challenging to overcome. A hard-right House of Representatives will be hard-nosed to support legislation or executive orders that legalizes marijuana in some context on the national level. While voters in both political parties and among independents all support marijuana liberalization, the elected officials from more conservative jurisdictions fail to represent their constituents when it comes to marijuana reform. Let’s consider the state of Louisiana, for example. The Reilly Center for Media and Public Affairs in Louisiana State University’s Manship School of Mass Communication conducted a survey in May 2023 that found about seven in 10 Louisiana residents support legal recreational marijuana use.

Only one in ten believe that marijuana use should not be legal.

Nine in 10 support medical cannabis legalization. This public opinion data was published as the state legislature, at the time, was drafting benchmark simple marijuana offense expungement legislation that was recently signed into law by Gov. John Bel Edwards, a Democrat. The new law, Act 342, grants individuals convicted of possessing up to 14 grams of cannabis on a first offense the right to petition courts for wiping off their criminal record after 90 days from the time of the marijuana conviction being handed down. This is a huge win for restorative justice efforts in a state that is notorious for police brutality, a history of racism, and being ruled by centrist Democrats and far-right Republican officials.

Disconnect, once again

While there is clear support for marijuana reform, U.S. Senator John Neely Kennedy of Louisiana, a former Democrat turn Republican amid the pro-Trumpist tide of far-right populism, is opposed to marijuana legalization. Or, in the words of OnTheIssues.org, Sen. Kennedy “strongly opposes legalizing marijuana,” citing a 2016 candidates’ survey that the former Democrat filled out at the behest of the ultra-religious conservative American Family Association. While recognizing that this information could be considered outdated, it is emblematic of what is happening across the United States. Voters in states that are traditionally Republican-leaning (right-wing) overwhelmingly support efforts to legalize and regulate recreational marijuana for adult consumption. While Louisiana is just one case, Vaping Post has reported on several other conservative states where the voters are in support of the legalization efforts but their elected officials seem to avoid listening to the majority. Lastly, consider Texas. Texas is the most populated Republican-leaning state in the union. It is also the second most populous state after the Democratic stronghold and the largest, California. Data from the University of Houston found that 67 percent of Texas voters support legislative efforts that would make recreational marijuana legal for any legal purpose and relegated to consumers aged 21 years or older. Far-right U.S. Sen. Ted Cruz of Texas is staunchly opposed to legalized marijuana. He is on record saying that “it’s illegal and because it’s harmful to you. It’s not healthy.” An overwhelming share of adult voters in the United States are in support of legalizing marijuana for either medical or recreational uses, data from Pew Research Center concluded — about 88 percent.

In this data, 59 percent believe that it should be legal across the country. 30 percent should be legal only for medical use. Only one in ten believe that marijuana use should not be legal. Considering this context, it is important to watch the descheduling efforts of those who operate businesses that manufacture and sell marijuana vaping products.
 
This is an op ed rather than a new article but it goes to the de-schedule review discussed in the post above.


Biden Review Must Fully Deschedule—And Not Merely Reschedule—Marijuana To Resolve State-Federal Conflicts (Op-Ed)

By Paul Armentano, NORML


Since California legalized the use of cannabis for medical purposes in 1996, there has existed a growing chasm between state-level marijuana policies and federal law.

Today, the majority of states and the District of Columbia authorize the state-licensed production and sale of cannabis to qualifying patients. Twenty-three of these states also regulate the possession and use of marijuana by adults.

Nonetheless, under the U.S. Controlled Substances Act (CSA) of 1970, the cannabis plant is classified as a prohibited controlled substance. The CSA exists to establish a unified legal framework in all 50 states for the regulation of certain substances deemed by federal agencies to pose varying degrees of abuse potential. For decades, the U.S. Drug Enforcement Administration (DEA) has been designated as the agency responsible for implementing and enforcing the CSA while the U.S. Food and Drug Administration (FDA) is designated with determining substances’ medical efficacy.

Since Congress’s enactment of the CSA, marijuana has been placed in the classification of Schedule I—the most restrictive category available under the law.

By definition, substances in this category must meet three specific inclusion criteria:
  1. The substance must possess “a high potential for abuse;”
  2. It must have “no currently accepted medical use” in the United States; and,
  3. The substance must lack “accepted safety for use…under medical supervision.”
Substances that do not meet these criteria are categorized in less restrictive federal classifications (Schedules II through V). Historically, these categories have been reserved for prescription medications that possess FDA market approval. That is why substances placed in these lower classifications are only legally available from licensed pharmacies and they are uniformly regulated by federal laws and agencies.

Alcohol and tobacco, two substances acknowledged to possess far greater dangers to health than cannabis, have never been classified under the CSA. (Over the counter cold medicines generally are not either. Neither are dietary supplements.) This is why state governments possess greater flexibility to regulate the production and sale of these products.

With respect to alcoholic beverages, for instance, states are the primary decision-makers regarding who sells these products (e.g., state-run stores versus privately licenses businesses), where they may be sold (e.g., supermarkets versus pharmacies versus ‘package stores,’ etc.) and what types of products are and are not permissible (e.g., for decades, certain states limited the sale in certain markets of beer above a certain percentage). By contrast, states possess no such flexibility when it comes to regulating scheduled prescription substances like oxycodone, diazepam (Valium) or carisoprodol (Soma).

Since 1972, the DEA has reviewed and ruled upon four separate petitions seeking to either deschedule or reschedule marijuana. The last time they did so was in 2016. In every instance, the agency—which has the final say on such matters—has decided to keep the cannabis plant classified as a Schedule I controlled substance. On one occasion, the agency even overruled a decision from its own administrative law judge to do so.

In recent months, there have been growing discussions regarding when the agency may once again rule on the matter of cannabis’s scheduling and what they will recommend. Some have suggested that the agency may call for the rescheduling of marijuana to a lower classification (e.g., Schedule III) and have opined that doing so would address many of the existing conflicts stemming from federal prohibition.

Such optimism is likely misplaced.

Specifically, reclassifying cannabis to a lower schedule within the CSA continues to misrepresent the plant’s safety relative to other controlled substances such as cocaine and methamphetamine (Schedule II), anabolic steroids (Schedule III), benzodiazepines (Schedule IV) or alcohol (unscheduled). But more importantly, rescheduling marijuana fails to provide states with the explicit legal authority to regulate it within their borders free from federal interference.

Simply put, federally rescheduling cannabis does nothing to address the growing and untenable divide between state and federal cannabis laws. Following rescheduling, state laws authorizing citizens to possess cannabis for either medical or social purposes would continue be in violation of the federal law, as would be the thousands of state-licensed operators who currently serve these markets. And the DEA would still possess the same authority it has now to crack down on these state-regulated markets should it elect to do so.

Some have suggested that rescheduling the cannabis plant may provide greater opportunities for investigators to conduct clinical research, but this result is also unlikely. That is because many of the existing hurdles to clinical cannabis research, such as the limits placed upon scientists’ access to source materials, are marijuana-specific regulations and predate cannabis’s Schedule I classification. Other impediments, such as requiring the U.S. Attorney General to approve marijuana-specific research protocols are statutory and are not specific to marijuana’s scheduling in the CSA.

For these reasons, I believe that the only productive outcome of the current scheduling review would be a recommendation to deschedule cannabis—thereby removing it from the CSA altogether and providing states with greater discretion to establish their own distinct marijuana policies. (A case in point: In 2018 Congress removed from the CSA hemp plants containing no more than 0.3 percent THC, as well as certain cannabinoids derived from them.)

Making this change would remove the threat of undue federal intrusion in existing state marijuana programs and would respect America’s longstanding federalist principles allowing states to serve as “laboratories of Democracy.” By contrast, rescheduling simply perpetuates the existing contradictions between state and federal cannabis laws, and it fails to provide any necessary legal recognition in the eyes of the federal government to either the state-licensed cannabis industry or those adults who use the plant responsibly in compliance with state laws.

Paul Armentano is the Deputy Director of NORML—the National Organization for the Reform of Marijuana Laws. NORML filed the first-ever cannabis rescheduling petition in 1972 and was a co-party to another 2002 petition. In 2014, Mr. Armentano served as the principal investigator for defense counsel in the federal case U.S. v Schweder et al., which challenged the constitutionality of cannabis as a Schedule I controlled substance.
 
I've never understood the "cannabis so much stronger than it was" argument. They still sell 151 proof rum and Everclear. But you don't drink a Colt 45 size bottle of either and you don't smoke joints that look like a Cuban double corona (uh, that's a large cigar size). Its BS to my mind.


Not on the DeSantis agenda for president: Decriminalizing cannabis



  • DeSantis wouldn't decriminalize pot as president, he said when asked about it by a South Carolina voter.
  • The Florida governor said last year that he didn't like the "putrid" smell.
  • But DeSantis did help advance access to medical marijuana in Florida.


Republican Gov. Ron DeSantis said legalizing cannabis would not be on his agenda if he's elected to the White House in 2024.

DeSantis, who did advance rules for medical cannabis use in Florida, said he wouldn't pursue legalization nationally, expressing concerns about more young people accessing weed.

The definitive statement from the 2024 candidate for president came after a voter, speaking on behalf of injured veterans, asked DeSantis to "please decriminalize marijuana in 2025" during a campaign event in Augusta, South Carolina, on Thursday.

"I don't think we would do that," DeSantis responded. "But what I have done in Florida is we have a medical program through our Constitution that the voters did. Veterans in those situations in Florida are actually allowed access — it's very controversial because obviously there are some people that abuse it and are using it recreationally."

DeSantis argued that cannabis has become more powerful than it used to be, though many proponents of decriminalization say the drug should also be better regulated and labeled once it's legal, in a similar way as alcohol, so that people understand how much they're consuming.

As part of his response, the governor touted a schools initiative led by his wife, Florida first lady Casey DeSantis, that educates children about the consequences of drug use. US policy should be geared toward keeping children "clear of drugs," he said, and asserted that legalization would make the drug more accessible to young people.

Increased legalization of marijuana isn't associated with a rise in youth use, a 2021 study in the Journal of the American Medical Association showed.

But part of DeSantis' response to the cannabis question focused on the US opioid epidemic, in which he pointed out that sometimes people think they're using one drug — even illicit cannabis — only to learn, often too late, that it's been laced with deadly fentanyl.

"We have too many people using drugs in this country right now," DeSantis said. "I think it hurts our workforce readiness, I think it hurts people's ability to prosper in life."

Unlike cannabis policy, the opioid crisis was spurred along legally by doctors' overly aggressive prescribing practices. The medical community heavily marketed pain medications and pushed regulators to approve widespread use. Companies eventually conceded — after lying about it for years — that the drug was addictive and being misused.

Patients abruptly lost access to painkiller medications and many turned to similar, illicit drugs such as heroin. Most-recent available data show 68,630 people died opioids in 2020.

DeSantis has a mixed record on pot

Marijuana is illegal under federal law and is listed as a "Schedule 1" drug like heroin and meth, meaning justice agencies view it as having "no currently accepted medical use and a high potential for abuse." The Biden administration is reviewing the scheduling by the end of this year.

President Joe Biden has previously expressed skepticism about all-out legalization but in October 2022 he pardoned all prior federal offenses of simple marijuana possession.

Florida voters passed a constitutional amendment in 2016 that legalized cannabis use for medical reasons; the amendment had the support of more than 70% of voters.

Soon after becoming governor in 2019, DeSantis succesfully convinced the legislature to lift a state ban on the smokable form of the drug — a move meant to help the ballot initiative go into effect, and one that stunned the political class.

As a US Congressman, DeSantis voted in favor of spending bill amendments to protect state cannabis programs from federal interference. But the governor, who is also a Navy vet, voted against legislation that would allow doctors to recommend cannabis to patients.

In Florida, proponents are working to bring a ballot measure before Florida voters in 2024 that would legalize cannabis for recreational reasons for people ages 21 and over. The initiative has secured enough signatures to be considered, though it faces other hurdles.

Before it can be on the ballot, it must first go before the state Supreme Court for review. It could also face a challenge from Republican Florida Attorney General Ashley Moody, a DeSantis ally.

Asked about cannabis support in 2022, DeSantis expressed some hesitancy on the issue and derided the "putrid" smell of the drug.

"I think a lot of those other areas that have done it you know have ended up regretting it," DeSantis said in 2022, according to Politico. "I could not believe the pungent odor that you would see in some of these places and I don't want to see that here. I want people to be able to breathe freely."

At the time, former Agriculture Commissioner Nikki Fried — a leading proponent of legalization in Florida who now chairs the state's Democratic Party — was running for the Democratic nomination for governor, though it ultimately went to former Charlie Crist, a former congressman.

On Capitol Hill, the issue of cannabis legalization has become more bipartisan, particularly as a growing number of states have made it available medically and recreationally. Gallup polling finds 68% of voters, including half of Republicans, say marijuana use should be legal.

Senate Majority Leader Chuck Schumer met with Republicans this year to see what types of legalization measures might pass, including changes that would allow more banks to lend to cannabis businesses Marijuana Moment reported.
 
I truly hate...fucking hate....politicians who do not recognize that their power...all of their fucking power....derives from the electorate. In this case, Carney's electorate overwhelmingly supported rec legalization yet he vetoed the legislation. The only reason it got passed the next year is that the DE legislators, apparently more sensitive to the ire of their voters, passed it again with a veto proof majority. In other words, they stuck it up Carney's ass and broke it off and good on them.

Carney is a short sighted idiot and if MJ was not rec legalized in DE, then his citizens would simply pop over a state line (MD goes full rec in a bit over a week and NJ has been)

His response....put this guy in charge. I hope DE kicks his ass to the curb next election.

Oh....and how do they have 60 grow licenses allowed and only 30 retail (dispensaries) allowed. That makes zero sense to me.



Marijuana legalization foe Gov Carney adopted an “old-fashioned’’ approach by naming a law enforcement veteran to regulate the new legal industry.​

1687474083263.png

Rob Coupe has been a leader of law enforcement in Delaware for the last 15 years.


He led the state police, Department of Correction, Department of Safety and Homeland Security, and was chief of staff for Attorney General Kathy Jennings. Currently, Coupe heads the state Department of Technology and Information.


Now, Gov. John Carney has tapped 60-year-old Coupe to oversee and regulate an industry Carney vehemently opposed in Delaware: legalized recreational marijuana.


Carney nominated Coupe as the state’s first marijuana commissioner earlier this month, and officials and observers say he’ll sail through a Senate confirmation hearing today.


“As I’ve said before, there are few people across our state who are more well-respected and more committed to serving the people of Delaware, than Rob Coupe,” Carney said in a statement when he nominated Coupe. “He’s exactly the right person to take on this new challenge.”


Carney successfully vetoed a bill to legalize weed and create a regulated retail market last year. But in April, with a looming veto override by a more progressive General Assembly, Carney let a legalization bill become law without his signature, and did the same with one to create a regulated retail market.


Coupe told WHYY News it “would be premature” to comment on his nomination. But State Rep. Ed Osienski, who sponsored both marijuana bills, endorsed Coupe for the post that will be part of the Department of Safety and Homeland Security — a department that Coupe headed for more than three years until March 2020.


The so-called “weed czar” will hire a staff to run an oversight office that will create copious regulations to govern growing, manufacturing, testing, and retail industries for marijuana. Starting next fall, the commissioner must begin the process of issuing 125 licenses for the marijuana market.


Here’s how the licenses will be allocated:


  • 60 for indoor and outdoor growing operations.
  • 30 for businesses that manufacture gummies, candies, oils, and other non-leaf products.
  • 30 for retailers.
  • Five for testers that must ensure quality and accuracy of products and labeling.
“Nobody has any more experience operating divisions under Homeland Security than Mr. Coupe does,’’ Osienski said. “So I think he was a good pick to get that work done.”


Osienski said one major factor is “who he picks as deputy director and other hires for the staff that may have some experience or knowledge in the industry. So that’s yet to be seen.”


He also said he has offered his assistance to Coupe, who responded that he “definitely would be reaching out to me so we can go over everything and he can get a better understanding of what my intent was’’ with the 45-page bill to create the retail market.


Osienski said Coupe’s challenges include understanding the new law and “propagating those regulations to come up with the best fair process of accepting applications and issuing licenses.”


Osienski thinks the new office could benefit from Coupe’s experience in policing since one of its goals is to eradicate the illegal market.


“One of the jobs that they are tasked with is making sure once we have this legal market set up, that the illegal market is done away with,’’ Osienski said. “So I think having somebody that has a background in enforcement would help along those lines.”


The lawmaker also pointed out that Coupe, who began his policing career in 1985, has avoided controversy in high-pressure posts.


“He does a good job in any position he’s been assigned to,’’ Osienski said. “There’s been no drama or issues.”


Having ex-cop as weed czar has ‘benefits but also drawbacks’​


Zoe Patchell of the Cannabis Advocacy Network of Delaware said she and others in her group are eager to meet with Coupe to “discuss regulations and weigh in, as stakeholders, on how to implement Delaware’s adult-use cannabis market.”


“Our concerns continue to be focused on creating a fair, equitable, competitive, and consumer friendly market that accomplishes the goals and intent that were written into the legislation.“


Peter Murphy, a Wilmington lawyer who has advised clients in Delaware’s longstanding medical marijuana market, as well as cannabis entrepreneurs in other states, said Carney has followed the “old-fashioned’’ model of naming someone with a law enforcement background to oversee his state’s weed industry.


Having a top regulator with a policing background was once “a common approach where we saw medical cannabis being legalized state by state. And it was based on the concerns of diversion and the amount of cash on hand, because it was almost exclusively a cash business,’’ Murphy said. “So you had this focus on diversion and dispensaries being possible targets for robbery or burglary.


That approach “does have benefits, but also has some drawbacks,’’ Murphy said. “It clearly prioritizes security and public safety concerns, possibly at the the expense of economic development or social justice.”


The new law calls for the commissioner to issue a total of 47 social equity licenses to people who have lived in areas “disproportionately impacted’’ by marijuana prohibition and enforcement, or were convicted of lower-level marijuana crimes.


“In the last five years, cannabis licensing and regulation has shifted toward more social justice concerns,’’ Murphy said.


In addition, those who received licenses often had a law enforcement background. This was the case in Delaware, where the first medical marijuana licensee was a former state trooper.


But the industry and the times have changed, Murphy said, and many states including Delaware now focus “on the fact that prohibition has harmed certain minority communities more than others. And as a result, we need to provide opportunities for those most negatively affected. So with that change, it definitely puts a different lens on having a law enforcement professional at running a program.”


Coupe could be confirmed as early as today. His nomination is scheduled to be discussed at the Senate Executive Committee’s meeting at 2 p.m., likely followed by a vote in the full Senate.
 
"The final decision isn’t up to the president in this situation. The first step will be for the U.S. Department of Health and Human Services (HHS) to complete an eight-factor scientific review into cannabis and submit its findings and recommendations to the Justice Department. The Drug Enforcement Administration (DEA) under DOJ would then have the final say on a scheduling determination."​
I believe this is poppycock....a nicer way of saying "this is BULLSHIT!". First, HHS, DOJ, and subsidiary bureaucracies like DEA and FDA, all work for and at the sufferance of the President. However, Presidents want political top cover, all politicians seem to lead from behind, and there's nothing like a faceless bureaucracy to provide deniability and evasion of responsibility.

As for Biden's options....there is one they do not mention and that's doing nothing which would be in concert with his long and well documented history as a anti-drug warrior.




Biden Admin Only Has Two Viable Marijuana Options, New Coalition Says In Report That Details Benefits Of Rescheduling



A newly formed coalition of marijuana businesses and advocacy organizations is making the case that the Biden administration really only has two viable choices when it comes to its ongoing federal scheduling review: remove cannabis from the list of banned substances altogether or reschedule it—the less ideal option of the two, but one that the group says would still come with significant benefits.

The Coalition for Cannabis Scheduling Reform (CCSR), which launched earlier this month, published a report on Monday that outlines the scientific, economic and societal considerations that are going into the scheduling review that President Joe Biden directed late last year.

While advocates—as well as the public overall—has come to embrace full legalization (i.e. descheduling), the new organization is hoping to influence the conversation in a way that acknowledges the potential opportunities that would come with an administrative decision to more incrementally move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedules III-V.

The report aims to illustrate those benefits, even as the coalition continues to push for complete descheduling.

The final decision isn’t up to the president in this situation. The first step will be for the U.S. Department of Health and Human Services (HHS) to complete an eight-factor scientific review into cannabis and submit its findings and recommendations to the Justice Department. The Drug Enforcement Administration (DEA) under DOJ would then have the final say on a scheduling determination.

HHS Secretary Xavier Becerra told Marijuana Moment earlier this month that it’s his hope that the agencies of jurisdiction will be able to complete its work by the year’s end, but that remains to be seen.

“Descheduling is the optimal outcome and the one that would mark the greatest improvement over the status quo possible without congressional intervention,” CCSR says in the new report. “Descheduling marijuana is sound public policy, supported by both the science and the law, as recent and compelling medical and public health data clearly demonstrate that marijuana simply does not belong in the CSA at all.”

However, if FDA “determines that it cannot find its way to recommending marijuana descheduling, the Agency should instead recommend rescheduling to schedule III, IV, or V.”

CCSR describes that various considerations—and pros and cons of both scenarios—at length in the report, which is broken down into five key sections.
Here’s a rundown of the group’s main arguments:

I. Full descheduling would achieve the most progress possible from the administrative process.

Removing marijuana from the CSA would help address racial inequities resulting from the drug war, lift economic barriers for the workers and businesses that exist in state markets and “go the farther toward aligning federal marijuana policy with the views of the 21st century American voters.”

“The downstream effects of enforcing marijuana’s schedule I status are staggering, producing disparities in policing, incarceration rates, wages, employment opportunities, wealth, and health outcomes,” the report says. “Descheduling would allow for greater equity in the justice system and provide a pathway for individuals who have been impacted by discriminatory marijuana policies to clear their records and access greater economic opportunities.”

Taking this step would be widely embraced by advocates and stakeholders. Even if it simply removing cannabis from the CSA wouldn’t “cure all that is wrong with federal marijuana policy,” it would “mark the most progress possible without federal legislation.”

“However, descheduling is not the only viable option for reform,” CCSR says.

II. Rescheduling to schedule III, IV, or V would mark a historic first step on the path to comprehensive reform.

As far as the coalition is concerned, keeping cannabis in Schedule I—the most strictly controlled category under the CSA—or even moving it one classification down to Schedule II would prove untenable from multiple scientific and policy angles.

But short of descheduling, a reclassification to Schedule III, IV or V “would have significant advantages over the status quo.”

One immediate benefit, the group explains, is that it would allow state-licensed cannabis businesses to take federal tax deductions that they’re currently prohibited from doing under an Internal Revenue Service (IRS) code known as 280E, which only affects people who sell substances in Schedules I and II.

CCSR also says that rescheduling would “diminish” the scope of criminal penalties that could be imposed on people for violating marijuana-related provisions of the CSA.

Moving cannabis to Schedule II, however, “would be an unacceptable and indefensible result under the law,” the report says. “Moreover, it would not only fail to address the President’s stated goals, but it also would present a substantial cost to American marijuana businesses.”

The coalition is further recommending that if that administration does decide to reschedule to III, IV or V, further action would be needed—namely, “FDA and DEA should issue enforcement guidance to minimize economic disruption, promote state-federal collaboration, and protect the public’s health.”

“Rescheduling marijuana to schedule III, IV, or V does not come without real and perceived obstacles,” the group acknowledges. “As a controlled substance, marijuana would still technically be subject to strict regulations governing its use, possession, distribution, and manufacturing. If enforced, these controls would pose significant challenges for the state-regulated marijuana industry, as access to marijuana and marijuana products would remain subject to DEA oversight and criminal enforcement authority.”

While an existing congressional appropriations rider restricts DEA from using its funds to interfere in state medical cannabis programs, CCSR identified ways that the agency could still disrupt state markets, particularly as it concerns the adult-use industry. “Thus, rescheduling would likely leave the marijuana industry under a lingering threat of federal enforcement similar to the one it operates under today,” it says.

III. The executive branch can accomplish meaningful reform through this administrative process without upsetting existing standards.
The third section of the report details how FDA and DEA have historically defended and upheld the Schedule I classification of marijuana under federal law and explains why the agencies “need not and should not reach the same conclusions today.”

Specifically, the coalition provides an analysis about how the “settled standards” of medical value and potential for abuse that are relied on to make scheduling decisions demonstrate that the only viable options for the administration are to either deschedule or reschedule to Schedules III-V.

For example, the fact that the vast majority of states have legalized medical cannabis, recognizing the plant’s utility for a variety of conditions, undermines the federal government’s position that there’s no currently accepted medical value—a key tenet of its current Schedule I classification.

Additionally, numerous academic and scientific institutions have affirmed that cannabis can be therapeutically beneficial to patients—and tens of thousands of studies have supported that conclusion.

IV. Marijuana’s low abuse potential confirms the propriety of descheduling or rescheduling to schedule III, IV, or V.
When it comes to marijuana’s potential for abuse—the other key criterion for the scheduling designation—the report again explains why cannabis does not meet the high threshold for its current Schedule I status.

“At least three developments since this determination powerfully confirm that the time for a new approach is now,” CCSR says. 1) Marijuana is widely considered a medicine at the state-level, 2) even when used for recreational purposes, it has a lower abuse potential than other substances in lower schedules or no schedule at all and 3) studies have suggested that cannabis may actually serve as an “exit drug” that could help people transition away from more addictive and harmful drugs, including opioids.

The coalition also makes an interesting argument about the relative abuse potential of marijuana compared to certain hemp-based cannabinoids that were federally legalized under the 2018 Farm Bill. While the report doesn’t name any specific hemp products that may be potentially more harmful, it contends that marijuana’s “abuse potential is lower than that of the intoxicating hemp products Congress descheduled.”

“In short, the health impacts associated with marijuana use are demonstrably less severe than those of many substances that are not scheduled at all and many others listed in schedules II–V,” it says. “And, unlike other controlled substances, there is a long history and current practice of marijuana being used in small doses without harmful effects.”

Additionally, there are “already marijuana-specific standards, good manufacturing practices (“GMP”) standards, and GMP certification bodies certifying marijuana businesses at the state level—and the “implementation of these existing state regulations for product safety lowers the abuse potential of marijuana.”

V. U.S. international treaty obligations should not prevent the executive branch from descheduling or rescheduling to schedule III or better.
One of the most common arguments that DEA has relied on to dismiss petitions for descheduling or rescheduling is the idea that taking that step would violate decades-old international treaties to which the U.S. is a party. CCSR’s report argues that those treaties should have no bearing on the government’s ultimate decision.
There are three main points to that end: 1) the president’s scheduling directive focuses on administrative authority of sections of statute that the coalition argues are unencumbered by the treaties, 2) the U.S. would still be out of compliance with the Single Convention if marijuana remains in Schedule I, because the federal government’s hands-off approach to state cannabis markets contravenes the treaties already and 3) “the Single Convention provides that signatory states need not comply with the treaty if doing so is incompatible with their constitutional framework.”
 
He's talking to the wrong people...us. His party has the Executive Branch, the majority in the Senate, and are the minority in the House but not by much. He should be giving this speech on the House floor, IMO.

If NCAA Can End Marijuana Ban, So Can The Federal Government, Congressman Says (Op-Ed)


“Perhaps this is the final stretch towards ending the failed war on drugs. If the NCAA is issuing a call for a reasonable, rational drug policy, can Congress be far behind?”


By Rep. Earl Blumenauer (D-OR)


The NCAA Committee on Competitive Safeguards and Medical Aspects of Sports is recommending the removal of cannabis from its list of prohibited substances. Likewise, it says that drug testing for college athletes should be limited to performance-enhancing drugs, and that cannabis does not enhance performance.

This is one more signal that we are finally nearing the end of the failed “War on Drugs.” With college sports getting on board, is there hope for the Veterans Administration and the Department of Justice?

Fifty years ago, Oregon started a revolution becoming the first state to decriminalize cannabis possession. Since then, attitudes towards cannabis have changed from public skepticism and fear to surging popularity. Growing acknowledgement by medical professionals of marijuana’s usefulness to treat an array of conditions and diseases cannot be ignored.

Some of the most outspoken supporters of medical cannabis are retired professional athletes. Former football players have described how cannabis was one of the few remedies that help control the pain that resulted from the punishment inflicted on their bodies after years of training and games.

Slowly, surely, America is coming to its senses on over a century of misdirected efforts to demonize and regulate the use of cannabis.

The consequences go far beyond the plight of athletes. This failed prohibition effort has inflicted untold harm on people of color, particularly Black Americans. One million or more had their lives unnecessarily disrupted by the unequal application of cannabis prohibition. Selective enforcement fell much more heavily on people of color with devastating effects on individuals and communities.

A young person caught on the wrong side of the law faces lifelong implications for housing, education, employment and—of course—incarceration. All for a prohibition which never had any justification—in fact, it was never implemented with the same zeal against white and privileged young people. The consequences continue to linger.

Marijuana use is the number one cause of failed drug tests. This in turn has contributed to the shortage of drivers and railroad workers among some of the most obvious examples. This has real consequences for young people who would both like to work, and who are needed on the job.

The insanity even reached the White House, where young people qualified to work at the highest levels of government were tripped up over past cannabis use. This is ironic for an administration that won the heavily contested presidential election for Arizona largely because an overwhelmingly popular vote on cannabis legalization passed.

Had cannabis not been on the ballot, there is no doubt that young voters would not have come to the polls. But it was, and they did. By overwhelmingly supporting legalization these young voters provided the 30,000-vote margin for President Biden’s victory.

There have been other halting steps as states continue to reform their outdated, ineffective and unfair cannabis policies. There continues to be new products and uses developed for medical cannabis. State legal industry employment is approaching 500,000 Americans. Sales are in the tens of billions of dollars, generating millions of dollars of state and local taxes.

It was positive that the administration took a small but meaningful step to pardon federal offenders and clear their records. It is also looking at the descheduling cannabis under the Controlled Substances Act.

There has been progress internationally as countries like Portugal and Netherlands look towards at an entirely different philosophy in managing controlled substances, including cannabis. Our neighbors in Latin America, Mexico and Canada have all moved towards legalization, illustrating how far out of step U.S. drug policy remains.

The House of Representatives has passed on seven different occasions legislation to enable state-legal cannabis companies to have banking services. This is critical to cut down the wave of violence and the unnecessarily stifling of legitimate businesses.

Perhaps this is the final stretch towards ending the failed war on drugs. If the NCAA is issuing a call for a reasonable, rational drug policy, can Congress be far behind? We can only hope and keep working to make the case.
 
I generally try to restrict my posts in this sub-forum to hard legalization articles and not stuff about commercial company operations/etc. But, I think we are seeing broad pressure on cannabis industry with a number of companies being in very precarious positions, consolidating/reducing operating sites, etc.

As for Medmen....I was in one of their dispensaries in L.V. and hated it. Had the Too Cool for School vibe, blasting music, idiotic glass topped cabinet with samples for you to shop from (just give me a fucking menu, please...and Planet 13 did the same...I don't get it), and the flower was dried out crap.

Just my one and only experience at one store only.


Cannabis pioneer MedMen names fifth CEO in 3 years as company teeters on brink of collapse


MedMen appoints Ellen Deutsch as CEO in Last-Ditch effort to salvage company amid impending financial collapse.​


Cannabis firm MedMen announced Wednesday its fifth CEO since 2020 with the appointment of Ellen Deutsch, who will be tasked with turning around the once-industry-leading company that now stands on the verge of a financial collapse fueled by high debt.


Key Facts​


Deutsch’s appointment is effective immediately, with former CEO and board chairman Michael Serruya saying Deutsch will oversee a restructuring plan that will bring it “into a new phase of growth,” though no specific growth strategies were shared in the announcement of her appointment.


In February, a regulatory filing revealed MedMen—which in 2018 became the first marijuana company to achieve a $1 billion valuation—had $137.4 million in debt and just $15.6 million in cash remaining on hand.


The filing also showed the company had already defaulted on some of its debt.


Interim CEO Edward Record will step down from his position and continue as a non-executive board member.


Big Number​


More than $1 billion. That was the valuation of MedMen in 2018, when it qualified as a “unicorn” company and was likened to the “Apple store of weed.”


Key Background​


Deutsch, who most recently served as the COO of cannabis company Stem Holdings, has a large responsibility as she becomes MedMen’s fifth full-time CEO in three years. The revolving door at the company’s chief executive position started after its co-founder, Adam Bierman, exited the role in January 2020. Bierman, who founded the company in 2010, departed after MedMen had burned through a significant amount of its cash and its stock dropped nearly 90%. Bierman was also hit with a lawsuit from one of the company’s former CFOs in 2019 that alleged MedMen had a hostile work environment and that company funds were used for excessive personal spending. The ex-CFO, James Parker, claimed in his suit that he was retaliated against for telling “the CEO and president what they were doing was not allowed and that [MedMen]


was not their personal piggy bank.” The Los Angeles company has since shuffled through several executives and faced multiple lawsuits.


Tangent​


MedMen is one of several cannabis retailers that has felt the pressure of several problems that have impacted the cannabis industry for several years, despite widespread legalization efforts making recreational marijuana now legal in 23 states. For example, a 2022 analysis from Green Market Report found that the overall debt carried by cannabis operators was reportedly more than $600 million. In California, which legalized the recreational use of cannabis in 2016, tight regulations and high taxes have hindered the profit-making abilities of MedMen and other firms like it. The illegal cannabis market has also proved to be a problem for retailers, maintaining steady flows of business in states like California, New York, Colorado and Michigan—with the former two states suffering the most from business lost to the unregulated cannabis market.
 
I personally believe that this article is a bit of hyperventilating fear mongering.

First, there have been plenty of product recalls for items and substances that are indeed controlled by Fed law/regulation. Have the Feds all over it is zero guarantee of enhanced product safety.

Second, the MJ we consume now is light years safer than the ditch weed we smoked for decades and the illicit market MJ that is still ubiquitous in some states...particularly those with heavy tax burdens.

Just my view.


Varying State Marijuana Rules Cause Confusion Amid Ongoing Federal Prohibition


Amid the growing acceptance and legalization of cannabis use across the country, a concerning reality has emerged: The state-by-state patchwork of safety regulations can leave marijuana consumers wandering through a haze of uncertainty, exposing them to potential risks.

Under federal law, marijuana is illegal—period. So, it’s up to individual states to determine their own regulations and safety standards.

Those inconsistent regulations are part of a broad debate about the U.S. cannabis industry. The 47 states that allow at least some cannabis use (cannabis is still illegal in Idaho, Kansas and Nebraska) have taken various approaches to issues such as the allowable amount of euphoria-inducing tetrahydrocannabinol, or THC, in a product.

“We don’t really know what’s going on behind the doors of each and every lab in each and every state,” said Anna Schwabe, a cannabis geneticist and the director of cannabis education, research and development for 420 Organics, in an interview with Stateline. “I don’t really have any sense of or any level of comfort for the numbers that they’re putting out.”

Most states require legal cannabis products to be tested by licensed laboratories for potency and for contaminants such as pesticides and heavy metals.

Still, the lack of uniform testing standards has led to inconsistent lab results. Some labs that test products on behalf of farms have been caught inflating THC levels to cater to the demand for potent products, leading to a practice called “lab shopping” by producers, according to Leafly, an online platform dedicated to all things cannabis.

“Some businesses will decide to contract with those labs because it means that their products will test stronger [in THC] and in theory, be more attractive to consumers,” said Morgan Fox, the political director for the National Organization for the Reform of Marijuana Laws, known as NORML. “This is pretty unethical, and also an unfortunate byproduct of a financially competitive testing market.”

Some states have had to issue recalls due to products being cleared for sale despite the presence of harmful contaminants. In May 2022, the Oklahoma Medical Marijuana Authority suspended Scale Laboratories’ testing license after regulators uncovered more than 140 approved samples with mold, salmonella or E. coli. The authority also recalled 99 products related to the lab’s alleged rules violations.

An estimated 64,000-pound marijuana recall in Michigan in 2021 was linked to at least 18 health complaints, including increased seizure activity, allergic reactions, paranoia and a chemical burning sensation.

The Oregon Liquor and Cannabis Commission, which regulates the production and sale of marijuana in that state, issued a recall in late June for several batches of cannabis flower that tested positive for mold and heavy metals, including cadmium and mercury. The recalled flower was harvested before testing requirements were updated to include tests for microbiological contaminants and heavy metals.

“Having some standards of operation across the board would dramatically decrease the variation that we see among labs, but then we would have to have some sort of regulatory oversight to make sure everybody is following the rules [on THC levels and testing practices], which we already don’t have,” Schwabe said.

Testing methods​

Labs across the country have different methods of testing cannabis for potency and contamination, which may be part of the reason why there’s so much variation, Schwabe said. Some states run the labs and have a more standardized testing approach, while others offer licenses to independent labs.

Inconsistent state cannabis regulations could have potentially dire implications for consumer health, according to a 2022 study published in the Environmental Health Perspectives journal. The study found that state-level regulatory disparities pose an increased risk of contaminant exposure for immunocompromised people who could contract potentially fatal infections, while also causing confusion among cannabis growers, manufacturers and testing laboratories.

The study also found that identical cannabis samples could be considered acceptable in one jurisdiction but not in others.

Cannabis consumers also face the challenge of navigating inconsistencies in THC potency and marijuana strain names across different dispensaries and states, Schwabe said.

“If you’re thinking that Durban Poison is your go-to strain to alleviate whatever symptoms you are having and it works well for you, if you wanted to refill your medicine in a different state or at a different dispensary, you might end up getting something that’s not what you’re used to,” Schwabe said.

What is permissible in one state may be prohibited or regulated differently in another, said Karmen Hanson, a senior fellow with the health program of the National Conference of State Legislatures, a think tank working on behalf of state lawmakers.

“Legislators generally want to just have a program that works for their state in the way that they feel is best for their state, and that’s why they all look different,” Hanson said in an interview with Stateline. “What’s going to work in Colorado isn’t going to work for North Dakota or Texas.”

Moreover, cannabis programs are constantly evolving as states learn from one another and adapt their laws and regulations based on factors such as emerging research or public health concerns, said Michelle Rutter Friberg, the National Cannabis Industry Association’s director of government relations.

“States are still very interested in the revenue, but they’re also more interested in things like getting rid of an illicit market, making sure that the products that people are consuming are safe or trying to end the war on drugs by legalizing cannabis and doing so in an equitable way,” Rutter Friberg said in an interview.

Keeping consumers safe​

Industry supporters say regulatory consistency also could steer consumers away from illicit sources, which can be even more dangerous.

“You don’t know what’s in it, especially at a time when we’re talking about things like fentanyl. That’s more of a reason now than ever to talk about the regulation of products like this,” Rutter Friberg said.

States have implemented various initiatives to ensure product safety and to protect consumers. In several states, including Colorado and Washington, edibles are limited to 10 mg of THC per serving, with a maximum of 10 servings or 100 mg of THC per package. In Connecticut, edibles are limited to 5 mg of THC per serving and a maximum of 100 mg of THC per package. And in Massachusetts, edibles are limited to 5.5 mg of THC per serving and up to 110 mg of THC per package.

The Colorado legislature in 2017 began prohibiting the production and sale of edibles shaped like humans, animals or fruits in an effort to reduce their appeal to children. Similar measures, including child-resistant packaging, have been implemented in other states to make cannabis products less accessible to children.

Some marijuana advocates argue that federal legalization could provide a solution by establishing consistent standards and harmonizing regulations across state lines. Alongside potential research funding, they say, federal legalization could be a way to streamline the cannabis industry and enhance consumer safety.

“If [the federal government] legalized it, that would open the doors tremendously and wipe out some of the issues that we have,” Schwabe said. “We could all work together as one industry and start working on some of the things we don’t know…and start working toward making it safe for everybody.”
 

Sponsored by

VGoodiez 420EDC
Back
Top